Brief: Simulations Plus Enters New Strategic Collaboration To Discover Anticancer Therapies Through Its Ai-Driven Drug Design Technology
28/03/2023 13:39
March 28 (Reuters) - Simulations Plus Inc SLP.O :
* SIMULATIONS PLUS ENTERS NEW STRATEGIC COLLABORATION TO
DISCOVER
ANTICANCER THERAPIES THROUGH ITS AI-DRIVEN DRUG DESIGN
TECHNOLOGY
* SIMULATIONS PLUS - PER TERMS OF COLLABORATION, CO TO
DEVELOP
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) MODELS FOR
EFFICACY AGAINST MTHFD2
Source text for Eikon: ID:nBw4V76Z6a
Further company coverage: SLP.O
((Reuters.Briefs@thomsonreuters.com;;))